Sullivan Mark sold $586K of DFTX

Sullivan Mark (Chief Legal Officer) sold 13,008 shares of Definium Therapeutics, Inc. (DFTX) at $45.03 ($0.59M total) on 2026-06-25 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Sullivan Mark
Published Jun 26, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 26, 2026, 8:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$DFTX
Neutral
medium confidence
Mentioned
$DFTX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DFTXNeutralLow
01

Why it matters

The only new fact is the disclosed open-market sale size, price, and that it was executed under a pre-arranged 10b5-1 plan.

02

Market read

Traders may monitor for follow-on insider activity, but this specific disclosure is unlikely to drive a fundamental repricing by itself.

03

What to watch

The filing does not state tax/financing motives; without context on prior sales or total insider ownership changes, the signal may be overstated.

Relevance 4/10Novelty 5/10Timing: after-hours/filing day (Form 4 filed 2026-06-26)

Background

The article is a SEC Form 4 insider transaction disclosure for Definium Therapeutics, Inc.

Company-level read

Ticker impact

$DFTXNeutralMedium confidence
Context

Definium Therapeutics’ CLO Sullivan Mark sold 13,008 shares on 2026-06-25 at $45.03 under a pre-arranged 10b5-1 plan.

Expected impact

Low near-term impact; any reaction is likely muted unless paired with other negative company news.

Evidence & confidence

Form 4 is a primary disclosure, but the sale is explicitly under a pre-arranged 10b5-1 plan and does not include new operational/financial information.

Market effects

No sector read-through; this is company-specific insider liquidity disclosure.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still be interpreted as reduced confidence by some traders, especially in thinly followed small caps.

Key entities

  • Definium Therapeutics, Inc.

    Subject of the Form 4 insider sale disclosure.

  • Sullivan Mark

    Chief Legal Officer who sold 13,008 shares.

  • 10b5-1 plan

    Pre-arranged plan indicating the sale timing was predetermined.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$DFTXHighAI 8/10

Definium Therapeutics Eyes FDA Filing for LSD Treatment After Three Positive Phase 3 Studies

Definium Therapeutics (DFTX) reported positive results from early studies of its LSD treatment for autism, showing consistent effects in participants. The company plans to file for FDA approval after completing Phase 3 studies. Definium is also addressing safety concerns and plans to study individuals with more profound impairments. The company's lead products include MM120 and DT402, currently in clinical trials for various disorders.

$DFTXMedAI 8/10

Definium (DFTX) Q3 2026 Earnings Call Transcript

Definium (DFTX) reported Q3 2026 earnings, highlighting FDA breakthrough therapy designations for DT120. The company plans an NDA filing in H1 2027 and shared positive clinical data for DT120 and DT402. DT120 showed significant improvements in anxiety and depression trials, with plans to expand into PTSD. DT402 showed early promise in autism spectrum disorder studies. The company is preparing for a potential launch, focusing on commercial infrastructure and provider engagement.

$DFTXMed

What Definium Therapeutics (DFTX) Said on Its Q3 Earnings Call

Definium Therapeutics (DFTX) reported Q3 earnings, highlighting progress in clinical trials for DT120 and DT402. DT120 showed tolerability in Phase 3 studies, with top-line results for Ascend expected in 2027. DT402's early autism study was halted after five participants showed consistent efficacy signals. R&D expenses rose to $46.1M, with a net loss of $51M, narrower than the previous year. The company plans commercial preparations for DT120, targeting a pricing range of $30,000-$75,000.

$DFTXHighAI 8/10

Why is Definium Therapeutics stock gaining today?

Definium Therapeutics (DFTX) shares rose 0.2% after reporting Q3 2026 results. The company narrowed its net loss to $50.96M, reported positive Phase 3 results for DT120 ODT in anxiety, and received FDA Breakthrough Therapy Designation for depression. Cash reserves increased to $1.05B. Analysts maintain a Buy consensus with raised price targets.

$DFTXHigh

Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent

Definium Therapeutics, Inc. (DFTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights Reported positive topline Phase 3 results from two Phase 3 studies of DT120 ODT in generalized anxiety disorder (GAD) Received FDA Breakthrough Therapy Designation for DT120 ODT